[go: up one dir, main page]

MX2022009463A - Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso. - Google Patents

Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.

Info

Publication number
MX2022009463A
MX2022009463A MX2022009463A MX2022009463A MX2022009463A MX 2022009463 A MX2022009463 A MX 2022009463A MX 2022009463 A MX2022009463 A MX 2022009463A MX 2022009463 A MX2022009463 A MX 2022009463A MX 2022009463 A MX2022009463 A MX 2022009463A
Authority
MX
Mexico
Prior art keywords
methods
coupled receptor
protein coupled
antibodies targeting
antibodies
Prior art date
Application number
MX2022009463A
Other languages
English (en)
Inventor
Cheng Liu
Eric L Smith
Renier J Brentjens
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2022009463A publication Critical patent/MX2022009463A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

El tema ahora descrito proporciona anticuerpos que se unen a GPRC5D y métodos de uso de los mismos.
MX2022009463A 2014-12-05 2017-06-05 Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso. MX2022009463A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088228P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
MX2022009463A true MX2022009463A (es) 2022-09-05

Family

ID=56092679

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017007247A MX2017007247A (es) 2014-12-05 2015-12-04 Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.
MX2022009463A MX2022009463A (es) 2014-12-05 2017-06-05 Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.
MX2022001878A MX2022001878A (es) 2014-12-05 2017-06-05 Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017007247A MX2017007247A (es) 2014-12-05 2015-12-04 Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001878A MX2022001878A (es) 2014-12-05 2017-06-05 Receptor acoplado a la proteina g dirigida a anticuerpos y metodos de uso.

Country Status (16)

Country Link
US (4) US10590196B2 (es)
EP (1) EP3227324A4 (es)
JP (6) JP6753851B2 (es)
KR (2) KR20230159637A (es)
CN (3) CN113429484A (es)
AU (3) AU2015357535B2 (es)
BR (1) BR112017011932A8 (es)
CA (1) CA2969886A1 (es)
IL (3) IL285101B2 (es)
MX (3) MX2017007247A (es)
MY (1) MY195115A (es)
PH (1) PH12017501039A1 (es)
RU (2) RU2725819C2 (es)
SA (1) SA517381664B1 (es)
SG (2) SG10201913937QA (es)
WO (1) WO2016090329A2 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016090329A2 (en) * 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
HUE057777T2 (hu) 2014-12-05 2022-06-28 Memorial Sloan Kettering Cancer Center Kiméra antigén receptorok, amelyek G-fehérje-kapcsolt receptort céloznak meg, és a receptorok alkalmazásai
SG10201913245UA (en) 2015-10-23 2020-02-27 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
KR20250072712A (ko) 2016-12-02 2025-05-26 앤젤레스 테라퓨틱스, 인코포레이티드 합성 면역 수용체 및 이의 사용 방법
WO2018147245A1 (ja) * 2017-02-07 2018-08-16 第一三共株式会社 抗ｇｐｒｃ５ｄ抗体及び該抗体を含む分子
SG10201913656TA (en) 2017-04-26 2020-03-30 Eureka Therapeutics Inc Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
JP2020530294A (ja) 2017-08-09 2020-10-22 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞を調製するための方法および組成物
ES2959953T3 (es) 2017-08-09 2024-02-29 Juno Therapeutics Inc Métodos para producir composiciones celulares genéticamente modificadas y composiciones relacionadas
WO2019051335A1 (en) 2017-09-07 2019-03-14 Juno Therapeutics, Inc. METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY
EP3693012A4 (en) 2017-10-05 2021-07-21 Daiichi Sankyo Company, Limited CYTOTOXIC T-CELL DEPLOYMENT COMPOSITION
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US20210254000A1 (en) 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
BR112020011215A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc processo para a produção de uma composição de células t modificadas
AU2018379094B2 (en) 2017-12-08 2025-09-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
SG11202009525VA (en) * 2018-03-30 2020-10-29 Eureka Therapeutics Inc Constructs targeting cd22 and uses thereof
US12473342B2 (en) 2018-04-27 2025-11-18 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
JP7395508B2 (ja) * 2018-05-16 2023-12-11 ヤンセン バイオテツク，インコーポレーテツド 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
AU2019316647A1 (en) 2018-08-09 2021-02-25 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
AU2019370705B2 (en) 2018-10-31 2026-01-22 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
JP7742773B2 (ja) 2018-11-01 2025-09-22 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
US20220184131A1 (en) 2019-05-01 2022-06-16 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
EP3983447A4 (en) 2019-06-14 2023-06-28 Dana-Farber Cancer Institute, Inc. Antibodies against muc1 and methods of use thereof
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
JP2022543553A (ja) 2019-07-31 2022-10-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｇｐｒｃ５ｄに結合する抗体
EP4004045A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Antibodies binding to gprc5d
KR20220066892A (ko) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
CN114929360A (zh) 2019-10-30 2022-08-19 朱诺治疗学有限公司 细胞选择和/或刺激装置及使用方法
US20230192869A1 (en) * 2019-12-06 2023-06-22 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
EP4097218A1 (en) 2020-01-28 2022-12-07 Juno Therapeutics, Inc. Methods for t cell transduction
CN115702164A (zh) * 2020-04-17 2023-02-14 詹森生物科技公司 生物合成糖蛋白群体
CN115803824A (zh) 2020-05-13 2023-03-14 朱诺治疗学股份有限公司 鉴定与临床反应相关的特征的方法及其用途
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
FI4274851T3 (fi) * 2021-01-05 2026-01-16 Lanova Medicines Dev Co Ltd Monoklonaalisia anti-gprc5d-vasta-aineita ja niiden käyttötarkoituksia
WO2022148370A1 (en) * 2021-01-05 2022-07-14 Lanova Medicines Development Co., Ltd. Anti-gprc5d monoclonal antibodies and uses thereof
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
US20250354978A1 (en) 2021-03-22 2025-11-20 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
CN117321417A (zh) 2021-03-22 2023-12-29 朱诺治疗学股份有限公司 确定治疗性细胞组合物的效力的方法
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
WO2022247804A1 (zh) * 2021-05-23 2022-12-01 上海祥耀生物科技有限责任公司 抗gprc5d抗体、其制备方法与用途
CN118159565A (zh) * 2021-11-05 2024-06-07 正大天晴药业集团股份有限公司 结合gprc5d的抗体及其用途
JPWO2023100829A1 (es) 2021-11-30 2023-06-08
CA3244652A1 (en) * 2021-12-31 2025-05-22 Kyinno Biotechnology Co., Ltd. Anti-GPRC5D Antibodies and Their Use
US20250092135A1 (en) * 2022-01-10 2025-03-20 Nanjing Leads Biolabs Co., Ltd. Antibody and use thereof
US20250101379A1 (en) 2022-01-28 2025-03-27 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
EP4477674A1 (en) 2022-02-09 2024-12-18 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2023227062A1 (en) * 2022-05-27 2023-11-30 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
CN120051297A (zh) 2022-06-30 2025-05-27 因达普塔治疗公司 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
WO2024017326A1 (zh) * 2022-07-21 2024-01-25 山东先声生物制药有限公司 抗gprc5d纳米抗体及其应用
KR20250047766A (ko) 2022-08-05 2025-04-04 주노 쎄러퓨티크스 인코퍼레이티드 Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
EP4658675A1 (en) 2023-02-03 2025-12-10 C3S2 GmbH Methods for non-viral manufacturing of engineered immune cells
CN121311765A (zh) 2023-04-18 2026-01-09 朱诺治疗学股份有限公司 评估治疗性细胞组合物的效力的细胞毒性测定
CN121464348A (zh) 2023-05-23 2026-02-03 朱诺治疗学股份有限公司 T细胞的激活标记物和评估t细胞激活的方法
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231408A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026025092A1 (en) 2024-07-26 2026-01-29 Juno Therapeutics, Inc. Synthetic promoters for t cell expression

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2195768A1 (en) * 1994-08-11 1996-02-22 Shuji Hinuma G protein coupled receptor protein, production, and use thereof
CN1824777A (zh) * 1999-09-24 2006-08-30 索尔瓦药物有限公司 新的人g蛋白偶联受体
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1463523A4 (en) * 2001-08-20 2005-08-10 Genentech Inc PROTEIN AND NUCLEIC ACID OF THE GENDER INDUCED BY GPCR-LIKE RETINIC ACID 1
JPWO2003055507A1 (ja) * 2001-12-27 2005-04-28 住友製薬株式会社 拒食症又は生活習慣病治療薬及びそのスクリーニング方法
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1581171B1 (en) * 2002-12-20 2012-06-27 Abbott Biotherapeutics Corp. Antibodies against gpr64 and uses thereof
WO2004072117A2 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN103524619B (zh) * 2006-08-03 2016-10-05 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
US9512236B2 (en) * 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2192922A4 (en) * 2007-09-17 2010-09-29 Univ California INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES
WO2009051633A1 (en) * 2007-10-15 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Gpcr crystalization method using an antibody
CN101808663B (zh) 2007-10-25 2015-09-30 特雷利斯生物科学股份有限公司 抗rsv g蛋白抗体
HUE034465T2 (en) 2008-02-11 2018-02-28 Cure Tech Ltd Monoclonal antibodies for tumor treatment
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
WO2012009790A1 (en) * 2010-07-22 2012-01-26 Schrader John W Cross-protective pathogen protection, methods and compositions thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
KR102332790B1 (ko) 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
EP3623380B1 (en) 2013-03-15 2025-10-22 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP3004337B1 (en) 2013-05-29 2017-08-02 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
CN106163547A (zh) 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
PE20170286A1 (es) * 2014-07-01 2017-03-30 Pfizer Diacuerpos heterodimericos biespecificos y sus usos
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016090329A2 (en) * 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
HUE057777T2 (hu) 2014-12-05 2022-06-28 Memorial Sloan Kettering Cancer Center Kiméra antigén receptorok, amelyek G-fehérje-kapcsolt receptort céloznak meg, és a receptorok alkalmazásai
SG10201913245UA (en) * 2015-10-23 2020-02-27 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
EP3436070A4 (en) 2016-03-29 2019-11-27 University of Southern California AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS
AU2017240233B2 (en) 2016-03-31 2022-07-14 University Of Southern California A highly sensitive and specific luciferase based reporter assay for antigen detection
JP7742773B2 (ja) * 2018-11-01 2025-09-22 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体

Also Published As

Publication number Publication date
JP2022103382A (ja) 2022-07-07
IL252646B (en) 2021-08-31
CN107206077B (zh) 2021-06-08
AU2015357535A1 (en) 2017-06-29
RU2017123545A (ru) 2019-01-14
EP3227324A4 (en) 2018-08-29
SG10201913937QA (en) 2020-03-30
SG11201704552TA (en) 2017-07-28
HK1243955A1 (zh) 2018-07-27
US20200123249A1 (en) 2020-04-23
JP7027482B2 (ja) 2022-03-01
PH12017501039A1 (en) 2018-03-05
IL252646A0 (en) 2017-07-31
US20200123250A1 (en) 2020-04-23
IL285101A (en) 2021-08-31
WO2016090329A2 (en) 2016-06-09
CA2969886A1 (en) 2016-06-09
IL285101B2 (en) 2024-03-01
JP2022044638A (ja) 2022-03-17
RU2725819C2 (ru) 2020-07-06
CN113429482A (zh) 2021-09-24
BR112017011932A2 (pt) 2018-01-16
US20180118822A1 (en) 2018-05-03
MY195115A (en) 2023-01-10
JP6753851B2 (ja) 2020-09-09
CN113429484A (zh) 2021-09-24
MX2017007247A (es) 2018-01-25
AU2015357535B2 (en) 2020-05-14
RU2020120613A (ru) 2021-12-06
CN107206077A (zh) 2017-09-26
SA517381664B1 (ar) 2021-12-27
WO2016090329A3 (en) 2016-07-28
EP3227324A2 (en) 2017-10-11
JP2024053016A (ja) 2024-04-12
AU2023270242A1 (en) 2023-12-14
JP2018504890A (ja) 2018-02-22
US20240076370A1 (en) 2024-03-07
US11566071B2 (en) 2023-01-31
KR20170108945A (ko) 2017-09-27
AU2020217320A1 (en) 2020-08-27
US10590196B2 (en) 2020-03-17
KR102602417B1 (ko) 2023-11-16
KR20230159637A (ko) 2023-11-21
IL307767A (en) 2023-12-01
NZ732567A (en) 2023-10-27
BR112017011932A8 (pt) 2022-11-08
RU2017123545A3 (es) 2019-12-11
JP2020191900A (ja) 2020-12-03
MX2022001878A (es) 2022-03-11
IL285101B1 (en) 2023-11-01
JP2020120684A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
PH12017501127A1 (en) Antibodies targeting b-cell maturation antigen and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
AU2015269219B2 (en) Mesothelin-targeted chimeric antigen receptors and uses thereof
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
NZ744340A (en) Anti-jagged1 antibodies and methods of use
AU2016222891A1 (en) Anti-DLL3 chimeric antigen receptors and methods of use
HK1243090A1 (en) Anti-cldn chimeric antigen receptors and methods of use